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Biomarker
Cognitive outcomeThe prognosis of cognitive improvement after cerebrospinal ﬂuid (CSF) shunting in idiopathic normal pressure
hydrocephalus (iNPH) remains uncertain, with no reports on CSF biomarkers related to long-term cognitive
prognosis. We performed a preliminary study of CSF biomarker protein levels for cognitive outcome
prognostication of two-year outcomes after shunt treated iNPH in 36 patients (13 women) with a median age
of 75 years (IQR 69–78). CSF biomarkers included soluble amyloid precursor proteins (sAPP, sAPPα, sAPPβ),
amyloid β (Aβ)1–38, Aβ1–42 and phosphorylated tau (p-tau), lipocalin-type prostaglandin D synthase (L-PGDS)/
β-trace, and cystatin C. The results clearly showed that p-tau levels (sensitivity of 71.4%, speciﬁcity of 77.8%,
cut-off value of 22.0 pg/mL), Aβ1–38/Aβ1–42 ratio (77.8%, 81%, 3.58), and the Aβ1–42/p-tau ratio (76%, 72.7%,
14.6) in preoperative CSF have the potential to determine postoperative prognosis. Improved cognition may be
associated with the improvement in CSF circulation after LPS, which likely induces cystatin C and L-PGDS and
switches synthesis from Aβ1–42 to Aβ1–38.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Idiopathic normal pressure hydrocephalus (iNPH) is increasingly
being regarded as important because of its disease speciﬁcity, leading
to cognitive disorder, gait impairment, dysuria, falls, and bedridden
status in the elderly [5]. Diagnosis of iNPH has progressed with the
release of new guidelines [15,20] and introduction of a cerebrospinal
ﬂuid (CSF) shunting procedure. However, the mechanism by which
shunt surgery improves the symptoms of iNPH is unclear. In the healthyrmal pressure hydrocephalus;
cale; MMSE, Mini Mental State
trail making test part A; mRS,
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operating characteristic; IQR,
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. This is an open access article underbrain, a balance is maintained between the production and absorption
of the CSF, with four or ﬁve CSF turnovers occurring each day. With in-
creasing age, however, people show increased resistance to CSF
absorption. In patients with iNPH, the turnover of CSF appears to have
declined more than average due to a reduced ability to absorb CSF [8].
A conspicuous decline in CSF circulation appears to affect themetabolism
of a variety of proteins that are produced intracerebrally. In the shunting
procedure, the CSF is drained into the abdominal cavity through the
shunt system, compensating for the loss of CSF absorption capabilities
caused by iNPH. It appears that CSF shunting not only corrects intracranial
pressure but also effectively promotes CSF turnover [33].
The prognosis after CSF shunting in iNPH remains uncertain even
after the establishment of the latest diagnostic criteria, and only a few
reports exist on biomarkers related to prognosis [30]. Most reports on
the clinical outcomes of CSF shunting for iNPH are the result of
short-term follow-up studies (about 1 year) [7,11], with no reports on
CSF biomarkers that predict long-term prognosis.
In this study, we explored the levels of CSF biomarkers for their
association with prognosis of cognitive functional outcome in shunt-
treated iNPH. We examined and compared patients whose activities of
daily living (ADL) improved after CSF shunting and those whose degree
of improvement was poor. We analyzed the changes in various
biomarkers, focusing on amyloid-related proteins in the CSF, and
explored those that may predict the cognitive functional prognosis ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to or associated with Aβ pathways [6,22].2. Material & methods
2.1. Patients
Sixty patients (15 women), mean age of 75 years [25% and 75%
interquartile range: interquartile range (IQR) 69–78]with iNPHdiagnosis
at the Department of Neurosurgery [16], Juntendo University in Tokyo,
Japan, based on existing guidelines [20], underwent lumboperitoneal
shunting (LPS) [23] between September 2008 and May 2012.
Inclusion criteria were symptoms and signs, andmagnetic resonance
imaging (MRI) ﬁndings compatible with iNPH [26]. Of these, 13
patients did not have CSF collected. Eleven patients were not
followed up, including 4 deaths. Thirty-six patients (13 women)
were re-examined 2 years after LPS, prior to this study (Fig. 1).
Postoperative course was analyzed using the modiﬁed Rankin Scale
(mRS) [37], Japanese iNPH grading scale (JNPHGS) [21], the Mini-
Mental State Examination (MMSE) [4], Frontal Assessment Battery
(FAB) [3], and Trail Making Test A (TMT-A) [27,28]. Performance was
compared before and 2 years after LPS.
In the ﬁrst classiﬁcation method, we compared two groups: the
“Improved Cognitive group”, who either maintained a favorable cognitive
function of 25 points or higher in MMSE score or improved by 3 points in
2 years after LPS surgery; and the “Poor Cognitive group”, whose MMSE
scores were less than 24 points without improvement of at least 3 points
after LPS surgery. CSF biomarkers were compared between groups.Fig. 1.Overview of patient selection. Four deaths: Four patients died during the course due tom
complications of liver cancer.In the second classiﬁcation method, we divided the subjects
according to age at surgery (60s, 70s, or 80s) and studied the degree
of symptom improvement.
2.2. CSF analysis
The study was approved by the Ethics Committee of Juntendo
University. All patients included in the study, or their relatives, gave
informed consent to their participation. Written informed consent was
also obtained from patients and families prior to LPS placement for all
patients who were positive for the tap test. LPS was performed using
adjustable valves in all patients, a non-siphon control (NSC)
valve with a small lumen catheter (Medtronic Neurosurgery, Goleta,
CA) [23].
Lumbar puncture (LP) was performed in the L3–L4 or L4–L5
interspace before LPS. The CSF before LPS was sampled through an
18G spinal needle. Two years after LPS, CSF was sampled again through
a puncture of the reservoir using a 27-gauge needle to conﬁrm that the
shunt systemwas operating effectively. No infectionswere reported fol-
lowing the tap test or shunt valve puncture. We obtained lumbar CSF
before and after LPS. All CSF samples were centrifuged to remove cells
and debris, aliquoted, and stored in polypropylene tubes at −80 °C
until biochemical analysis [18].
Shunt reservoir and lumbar CSF biomarkers were also compared.
CSF biomarkers included total soluble amyloid precursor proteins
(sAPP)α and β, amyloid β (Aβ)1–38, Aβ1–42 [32], and phosphorylated
tau (p-tau) [29]. We also measured lipocalin-type prostaglandin D
synthase (L-PGDS)/β-trace and cystatin C, a known chaperone of
Aβ protein. The bicinchoninic acid (BCA) method was used for totalyocardial infarction, malignant lymphoma, suffocation due to foreign body aspiration, and
Table 1
Kits used for ELISA and immunoprecipitation.
Target
protein
Name of reagent kit Supplier
sAPP Human sAPP, Total (highly sensitive) Assay Kit No27731 IBL, Takasaki, Japan
sAPPα Human sAPPα (highly sensitive) Assay Kit No27719 IBL, Takasaki, Japan
sAPPβ Human sAPPβ (highly sensitive) Assay Kit No27732 IBL, Takasaki, Japan
Aβ1–38 Human Amyloidβ1–38(FL) Assay Kit No27717 IBL, Takasaki, Japan
Aβ1–42 Innotest beta-amyloid 1–42 Innogenetics, Belgium
L-PGDS Human prostaglandin D synthase
(lipocalin-type) ELISA
RD191113100R, BioVendor, Brno, Czech Republic
Cystatin C Human cystatin C ELISA RD191009100, BioVendor, Brno, Czech Republic
P-tau Innotest phospho tau-181p Innogenetics, Belgium
sAPP; total soluble amyloid precursor protein, Aβ; amyloid beta, L-PGDS; lipocalin-type prostaglandin D/β-trace, p-tau; phosphorylated tau.
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(ELISAs) were used for other biomarker measurements (Table 1)
[17].
2.3. Data analyses and statistics
Non-parametric statistical methods were used for all data analysis.
TheWilcoxon signed-rank test was used for within-group comparisons
ofmRS, JNPHGS,MMSE, FAB, and TMT-A scores before and after LPS, and
the Mann–Whitney U test for comparisons between the “Improved
Cognitive group” and “Poor Cognitive group”. Dunnett's T3 test was used
to compare age groups (60s, 70s, and 80s). These data are presented
as medians (95% credible interval). Statistical analyses were performed
with IBM Statistical Package of the Social Sciences Version 18.0 (SPSS,
Cary, NC) for Windows. p b 0.05 determined with a t-test was consid-
ered signiﬁcant.
3. Results
Table 2 shows mRS, JNPHGS, MMSE, FAB, and TMT-A scores before
and 2 years after LPS treatment in patients with iNPH (n = 36).
Improvements were observed after shunt surgery, with statistically
signiﬁcant differences in all mRS and JNPHGS (gait, cognition, urinary
function) scores. LPS surgery related mortality or morbidity or signiﬁ-
cant postoperative complications were not observed. The p-tau,
Aβ1–38/Aβ1–42, and Aβ1–42/p-tau ratios predicted prognosis of cognitive
function. A group-speciﬁc analysis is shown below.Table 2
Neurological symptoms and cognitive evaluations before and 2 years after LPS surgery (n = 3
All iNPH patients (n = 36) Improve
Age median (IQR) 75 (69–78) 74 (68–
MMSE median (IQR) Before 22 (19–26) 23 (18.5
After 25 (20–28) 27 (25–
mRS median (IQR) Before 3 (2–3) 3 (2.5–
After 2 (1–2.5) 2 (1–2
JNPHGS gait
median (IQR)
Before 2 (1–3) 2 (1–3
After 1 (0–2) 0 (0–1
Cogn. median (IQR) Before 2 (1–3) 2 (1–3
After 1 (0–2) 0 (0–1
Urin. median (IQR) Before 2 (1–3) 2 (1–2
After 1 (0–1) 1 (0–1
Total median (IQR) Before 7 (4–8) 6 (4–7
After 3 (2–5) 2 (1–4
FAB median (IQR) Before 13 (11–14) 12 (10.2
After 13 (11–14) 13 (11–
TMT-A
median (IQR)
Before 91 (58–150) 90 (56–
After 77 (49–107) 69 (49–
IQR 25% and 75%.
Abbreviations: IQR; interquartile range, JNPHGS; Japan NPH grading scale, Cogn; cognition, Ur
FAB; frontal assessment battery, TMT-A; trail making scale-A, LPS; lumboperitoneal shunt.
After dividing the subjects into groups according to the degree of MMSE improvement, the onl
signiﬁcant differences were seen in cognitive function (MMSE, FAB, TMT-A). All items, except
signed-rank test.
⁎ p b 0.05.3.1. Comparison between the “Improved Cognitive” and “Poor Cognitive”
groups
The CSF biomarkers were compared between “Improved Cognitive
group” and “Poor Cognitive group” (Fig. 2). Receiver operating character-
istic (ROC) analysis was performed. Simple ROC analyses were
performed for each biomarker to distinguish “improved” cognition
(Table 3, Fig. 3). Statistically signiﬁcant differences were seen in the
following CSF biomarkers prior to surgery in the “Improved Cognitive
group”: p-tau, area under the curve (AUC) = 0.733, p = 0.046
(Fig. 4A); Aß1–38/Aß1–42, ratio, AUC = 0.804, p = 0.009 (Fig. 4B); and
Aß1–42/p-tau ratio AUC= 0.753, p = 0.017 (Fig. 4C). The cut-off values,
sensitivity, and degree of speciﬁcity were 22.0 pg/mL, 77.8%, and 71.4%
for p-tau; 3.58 pg/mL, 77.8%, and 81% for Aß1–38/Aß1–42 ratio; and 14.6,
76%, and 72.7% for Aß1–42/p-tau ratio.
Analysis of the Aβ1–38/Aβ1–42 ratio revealed that, while the
“Improved Cognitive group” showed a tendency to shift from Aβ1–42 to
Aβ1–38 (y = 1.9253x + 526.81 before shunt surgery versus y =
3.9725x− 270.11 two years after surgery), the “Poor Cognitive group”
showed almost no change (y = 2.509x + 1047.4 before surgery and
y = 2.1632x + 2255.7 two years after surgery) (Fig. 5).3.2. Comparison of age groups
Table 4 shows age-speciﬁc analyses, with 64.0 (IQR 61.0–66.5) years
(n=9) for subjects in their 60s; 75.5 (IQR73.0–78.0) years (n=22) for6).
d Cogn. (n = 25) Poor Cogn. (n = 11) p-Value (Improved vs Poor)
77) 78 (73–79) 0.075
–26) 22 (20–24) 0.512
29) 20 (19–21) ⁎0.000
3.5) 3 (3–4) 0.154
.5) 3 (2–3) ⁎0.038
) 3 (2–3) 0.616
) 2 (1–3) 0.197
) 2 (2–3) 0.172
) 2 (1–3) ⁎0.001
.5) 3 (2–3) ⁎0.037
) 1 (1–2) ⁎0.028
) 8 (7–9) ⁎0.03
) 5 (3–8) ⁎0.003
5–14) 12 (8.5–12) ⁎0.029
14) 12 (8.5–14.25) 0.0514
157) 102 (83.5–187.5) 0.414
107) 85 (41–112) 0.982
in; urinary function, mRS; modiﬁed Rankin Scale, MMSE; mini-mental scale examination,
y signiﬁcant differences between groups were seen in the iNPHGS gait and total score. No
FAB, improved signiﬁcantly after LPS. Statistical analysis was performed by the Wilcoxon
Fig. 2. Comparison of MMSE between the improved cognitive group and poor cognitive group. MMSE comparison between the improved cognitive (n = 25) and poor cognitive groups
(n = 11) 2 years after surgery (Before vs. After LP shunt).
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in their 80s. Comparisons of these groups revealed no signiﬁcant
differences in preoperativemRS scores between the 60s and 70s groups,
but a signiﬁcant difference of p = 0.032 was seen between the 60s and
80s groups. Preoperative MMSE scores showed no statistically signiﬁ-
cant differences among the different age groups. Although mRS scores
had improved in all age groups 2 years after LPS, a signiﬁcant difference
(p = 0.031) was seen in the 60s and 80s groups (Fig. 6). An evaluation
2 years later revealed that the group of patients who had undergone
shunt treatment in their 80s showed only slight improvements in
cognitive function (Table 4).
4. Discussion
We previously reported that measurement of sAPPα in the CSF is
useful for differential diagnosis of iNPH [19]. CSF amyloid precursor pro-
tein (sAPP, sAPPαand sAPPβ) levels in iNPH patients are signiﬁcantlyTable 3
CSF biomarkers before and after shunt treatment by cognitive function.
Improved Cognition group
(n = 25)
Poor Cognition group
(n = 11)
Before
sAPP (ng/mL) Median 457.0 581.0
IQR (335.5–650.0) (390.0–896.0)
sAPPα (ng/mL) Median 124.0 143.0
IQR (71.5–171.5) (98.8–166.0)
sAPPβ (ng/mL) Median 141.0 138.0
IQR (99.0–177.0) (88.0–191.0)
Aß1–38 (pg/mL) Median 1339. 0 1822.0
IQR (767.0–2045.0) (975.0–3029)
Aß1–42 (pg/mL) Median 486.0 263.0
IQR (290.0–587.0) (220.5–446.0)
Aß1–38/Aß1–42 Median 2.0 6.0
IQR (2–3.5) (3.5–6.5)
P-tau (pg/mL) Median 20.0 29.0
IQR (16–23.5) (23.0–39.0)
Aß1–42/p-tau Median 23.0 10.0
IQR (14.5–29.0) (8.0–17.0)
L-PGDS (μg/mL) Median 10.5 15.0
IQR (8.0–12.8) (9.0–17.0)
Cystatin C (μg/mL) Median 1.58 1.8
IQR (1.32–2.41) (1.62–3.01)
Protein (mg/dL) Median 36.5 35.0
IQR (32.5–44.8) (32.0–44.0)
IQR 25% and 75%.
Statistical analysis was performed by Mann–Whitney U test.
Group with “Improved Cognition”: MMSE ≥25 or improvement of 3 points, and “Poor Cognition
ratio and Aß1–42/p-tau ratio prior to surgery and 2 years after LPS, predicted improvement of M
⁎ p b 0.05.lower than in normal control subjects of all age groups. In this study,
the levels of these APP CSF biomarkers did not change within 2 years
after the shunt.
An analysis of iNPH shunt treatment and cognitive function showed
that the group whose MMSE scores did not improve 2 years after
surgery tended to have had low MMSE scores before surgery. CSF
biomarkers p-tau, Aβ1–38/Aβ1–42 ratio, and Aβ1–42/p-tau ratio [10,13]
were prognostic predictors of cognitive function (Table 3). Moreover,
analysis of the Aβ1–38/Aβ1–42 ratio revealed that, while the “Improved
Cognitive group” showed a tendency to shift from Aβ1–42 to Aβ1–38
2 years after surgery, the “Poor Cognitive group” showed similar results
before and 2 years after the same. Concentrations of Aβ1–38 and
Aβ1–42 increased after shunt treatment, perhaps due to a change in
γ-secretase activity [12].
In age-speciﬁc analyses of the 60s, 70s, and 80s groups, following the
iNPH diagnostic guidelines and performing shunting treatment, all age
groups attained improved mRS scores; however, younger age at thep-Value Improved Cognition group
(n = 25)
Poor Cognition group
(n = 11)
p-Value
After (2 years)
0.229 573.0 553.5 0.243
(3502.0–1109.0) (295.0–939.3)
0.505 165.0 159.0 0.505
(116.0–210.0) (129.0–259.0)
0.868 177.0 168.0 0.346
(132.0–228.0) (129.5–189.0)
0.08 2821.0 3732.0 0.099
(1924.0–3599.0) (2332.0–5474.0)
0.133 825.0 859.5 0.981
(749.0–911.0) (382.3–994.8)
⁎0.009 3.0 5.0 ⁎0.019
(3.0–4.0) (3.5–6.0)
⁎0.008 45.0 68.0 0.245
(28.0–69.5) (28.8–102.5)
⁎0.017 18.0 10.0 0.067
(11.5–29.0) (8.0–16.5)
0.139 18.0 17.0 0.33
(9.5–19.0) (11.0–27.0)
0.223 2.41 3.78 0.554
(2.05–3.83) (1.59–4.62)
0.831 40.0 42.5 0.541
(36.0–43.8) (32.3–50.8)
”: MMSE ≤24 without improvement of 3 points. Preoperative p-tau values, Aß1–38/Aß1–42
MSE.
ng/mL APP total APPα APPβ
Aβ42Aβ38pg/mL Aβ38/Aβ42
Protein p-tau Aβ42/p-taupg/mL
ng/mL ng/mL
pg/mL
mg/dL
µ/mL µ/mL Cystatin C
MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24
MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24
MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24
MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24 MMSE ≥25, ≤24
MMSE ≥25, ≤24 MMSE ≥25, ≤24
*
*
*
L-PGDS
Before After Before After Before After
Before After Before After Before After
Before After Before After Before After
Before After Before After
Fig. 3. Changes in CSF biomarkers in the improved and poor cognitive function groups. CSF biomarker changes in the improved (n= 25) and poor cognitive group (n= 11) 2 years after
surgery (before vs. after LP shunt); p b 0.05.
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The group that underwent treatment in their 80s saw slight improve-
ments; however, their MMSE values 2 years later were low and their
p-tau was high despite a high Aβ1–42/p-tau, indicating the severity of
neuronal damage and loss, suggestive of advanced pathological changes
associated with Alzheimer's disease (AD) impacting their cognitive
skills [1].
It should be noted, however, that these study ﬁndings are the result
of single-center experiences targeting an extremely small number of
subjects. In addition to our small sample size, this study, similar to
previous clinical studies on iNPH, has several further limitations related
to the patients' comorbidities [14]. In these studies, AD comorbidity
could not be excluded before shunting. Large-scale clinical studies areneeded to determine whether early initiation of shunt treatment can
contribute to improved cognitive function.
Both improved and poor cognitive groups showed a rise in the con-
centration of L-PGDS and cystatin C in the CSF after the shunt treatment.
L-PGDS, which is one of the most abundant CSF proteins and acts as a
prostaglandin D2-producing enzyme and a lipophilic ligand-binding
protein, is produced in the arachnoid membrane of the brain, spinal
cord, and oligodendrocytes. Its lipophilic nature allows it to function
as a chaperone, preventing the formation of neurotoxic agents such as
Aβ ﬁbrils [36]. It is thought to be secreted into the CSF as a β-trace
protein, and combines with different Aβ fragments with a high level
of afﬁnity to constantly suppress Aβ aggregation [9]. Image data of the
disproportionately enlarged subarachnoid-space hydrocephalus
Fig. 4. Receiver operating characteristic (ROC) curves of ELISA data from the ‘validation’ cohort. ROC analyses of the ‘validation’ cohort ELISA data were performed for each biomarker to
distinguish good cognition from poor cognition. A step-wise logistic regression model was applied to identify a complementary combination of biomarkers that would optimize accuracy
(maximize area under the curve (AUC) without including additional non-contributory biomarkers, accepted). Preoperative (A) CSF p-tau, AUC = 0.733, p = 0.046; (B) Aß1–38/Aß1–42,
AUC = 0.804, p = 0.009, and (C) Aß1–42/p-tau's AUC = 0.753, p = 0.017.
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reduced in iNPH [24]. Our study showed a trend of increasing L-PGDS
levels in the “Improved Cognitive group,” but no increase in the “Poor
Cognitive group” (Table 4).
Cystatin C is also involved in the metabolism of Aβ protein and is
chieﬂy secreted from the choroid plexus [35]. In iNPH pathology,
where the circulation of CSF is chronically impaired, ﬂuid secretion
from the choroid plexus into the CSF is also reduced [25,34], including
cystatin C. In patients with iNPH, cystatin C levels were low, but
increased after LPS treatment.
Choi et al. reported that Aβ polymerization (formation of Aβ
oligomers) was promoted by delaying the ﬂow of interstitial ﬂuids in
a culture experiment [2]. The results of animal experiments suggest
that 10–15% of Aβ is metabolized by interstitial ﬂuids [31]. The extent
to which the pathology of iNPH accounts for the reduced turnover of
CSF and themetabolism of Aβ is unclear. It is possible that the reduction
in enzymes related to Aβ metabolism such as L-PGDS and cystatin C
in iNPH creates an environment where Aβ aggregation is increased,
forming highly neurotoxic Aβ oligomers. After CSF shunt treatment,
turnover of CSF appears to increase, thereby increasing the produc-
tion of CSF, inducing cystatin C secretion from the CSF choroid
plexus, and L-PDGS from the arachnoid membrane of the brain,
spinal cord, and oligodendrocytes, thus promoting the metabolism
of Aβ.Fig. 5. Aβ1–38/Aβ1–42 ratio improvements in the improved (n= 25) and poor (n = 11) cognitiv
dency to shift fromy=2.0895x+419.3 before surgery to y=3.7455x−129.2 twoyears after s
changes two years after surgery, with y = 2.132x + 1075.5 before and y = 1.96905x + 2491.5. Conclusions
P-tau levels and the Aβ1–38/Aβ1–42 and Aβ1–42/p-tau ratios in
preoperative CSFmay serve as biomarkers for the prognosis of cognitive
function after shunt surgery in iNPH. However, in the age ≥80 operated
group, functional prognosis of cognition remains conﬁned, especially on
MMSE values. We suggest improved CSF circulation in iNPH after LPS
increases the amount of cystatin C and L-PGDS, possibly contributing
to Aβ elimination and improvement of a range of symptoms. The switch
in Aβ-variant synthesis from Aβ1–42 to Aβ1–38 also resulted in the
improvement of functional prognosis.Conﬂicts of interest
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Table 4
Age-speciﬁc changes (60s, 70s, and 80s) of mRS, MMSE scores, and various CSF biomarkers in idiopathic normal pressure hydrocephalus.
60s (n = 9) 70s (n = 22) 80s (n = 5) 60s (n = 8) 70s (n = 19) 80s (n = 5)
AGE Median 64 75.5 82
IQR 61.0–66.5 73–78 80–83
Before After
mRS Median 3.0 3.0 4.0 1.0 2.0 3.0
IQR 2–3.5 3.0–4.0 3.0–4.0 0–2.0 1.0–3.0 2.5–4.0
MMSE Median 22.0 22.5 18.0 25.0 26.0 19.0
IQR 20.0–25.5 18.25–26.25 16.5–25.0 21.5–28 20.5–28.0 18.0–25.0
sAPP total (ng/mL) Median 348.00 534.00 665.0 894.5 546.0 573.0
IQR 250.0–542.0 385.0–731.0 358.5–819.5 662.5–1124.0 461–1097 1340.0–639.0
sAPP α (ng/mL) Median 124.0 135.0 150.0 156.5 167.00 129.0
IQR 73–195 91.25–194.25 85.5–161.0 104.5–292.5 132.75–210.00 105.0–169.5
sAPP β (ng/mL) Median 134.0 146.0 252.0 159.5 171.0 228.0
IQR 97.0–183.5 100.0–173.0 92.0–420.5 101.5–210.0 129.0–215.0 145.0–247.0
Aß1–38 (pg/mL) Median 930.00 1762.0 1293.0 3245.0 3171.0 2480.0
IQR 721.25–2448.75 909.0–2316.5 952.0–2022.5 2388.0–4356.5 2122.0–4747.0 2016.5–2727.5
Aß1–42 (pg/mL) Median 329.00 491.5 457.00 905.0 823.0 659.0
IQR 184.00–549.50 258.0–603.5 274.75–559.0 827.5–1007.0 724–901 409.0–747.0
Aß1–38/Aß1–42 Median 2.30 3.55 2.24 3.41 4.09 3.93
IQR 1.83–8.77 3.28–5.18 1.99–4.73 2.49–4.44 2.62–5.93 2.54–5.81
P-tau (pg/mL) Median 20.0 22.0 24.0 38.50 53 38.0
IQR 16.0–22.5 16.0–27.0 17.5–30.0 15.00–67.25 37–84 20.5–65.25
Aß1–42/p-tau Median 16.45 19.60 23.22 25.33 12.02 13.19
IQR 10.11–27.70 10.23–29.19 12.23–28.19 13.96–36.99 9.79–22.24 9.13–43.94
L-PGDS (μg/mL) Median 12.00 11.50 10.00 10.05 19 13.0
IQR 7.57–17.00 8.78–15.0 8.02–11.00 8.56–17.75 16–25 5.48–16.75
Cystatin C (μg/mL) Median 1.58 1.81 1.40 1.90 2.61 3.23
IQR 1.23–2.08 1.52–2.93 0.92–1.69 1.52–3.90 2.22–4.17 1.84–3.51
Protein (mg/dL) Median 36.50 39.00 32.0 40.0 41.0 40.5
IQR 28.00–47.75 34.00–45.25 25.0–35.5 335.5–42.5 34.0–51.5 34.5–50.25
Whenmultiple comparisons weremade by age, statistically signiﬁcant differences were seen prior to surgery in the APP total (60s vs. 70s, p= 0.044) and L-PGDS (70s vs. 80s, p= 0.044)
in the CSF. Two years after shunt surgery, Aß1–42 (60s vs. 70s, p = 0.046) and L-PDGS (60s vs. 70s, p = 0.034) showed statistically signiﬁcant differences.
AlthoughmRS scores improved in all age groups (60s p=0.016, 70s p=0.001, 80s p=0.157), the 80s group showed almost no improvements in cognitive function 2 years after LPS (p=
0.683).
Fig. 6. Comparison of mRS scores in iNPH (60s, 70s, and 80s); before and after LP shunt.
Analyses by age group (60s, 70s, and 80s) revealed a signiﬁcant difference in preoperative
mRS between the 60s and 80s groups (p = 0.031).
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